Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.

Saved in:
Bibliographic Details
Title: Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Authors: Tanaka H; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan., Enokida T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Fujisawa T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Tanaka N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Takeshita N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan., Onaga R; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hoshi Y; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan., Wada A; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sato M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Ueda Y; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan., Tahara M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Source: Frontiers in oncology [Front Oncol] 2023 Nov 21; Vol. 13, pp. 1221352. Date of Electronic Publication: 2023 Nov 21 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2023.1221352